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Haploinsufficiency of TBX1, encoding a T-box transcription factor, is largely responsible for the
physical malformations in velo-cardio-facial/DiGeorge/22q11.2 deletion syndrome (22q11DS)
patients. Cardiovascular malformations in these patients are highly variable, raising the question as
to whether DNA variations in the TBX1 locus on the remaining allele of 22q11.2, could be
responsible. To test this, a large sample size is needed. The TBX1 gene was sequenced in 360
consecutive 22q11DS patients. Rare and common variations were identified. We did not detect
enrichment in rare SNP number in those with or without a congenital heart defect. One exception
was that there was increased number of very rare SNPs between those with normal heart anatomy
compared to those with right-sided aortic arch or persistent truncus arteriosus, suggesting
potentially protective roles in the SNPs for these phenotype enrichment groups. Nine common
SNPs (MAF >0.05) were chosen and used to genotype the entire cohort of 1,022 22q11DS
subjects. We did not find a correlation between common SNPs or haplotypes and cardiovascular
phenotype. This work demonstrates that common DNA variations in TBX1 do not explain variable
cardiovascular expression in 22q11DS patients, implicating existence of modifiers in other genes
on 22q11.2 or elsewhere in the genome.
Keywords
22q11.2 deletion syndrome; TBX1 sequencing; cardiovascular defects; genomic disorder
Introduction
Velo-cardio-facial syndrome/DiGeorge syndrome, also known as 22q11.2 deletion
syndrome (22q11DS; MIM#s 192430, 188400), is a congenital malformation disorder
characterized by craniofacial anomalies, immune deficiency, neonatal hypocalcemia and
cardiac outflow tract (conotruncal) defects. It occurs in approximately 1/4,000 live births
(Burn and Goodship, 1996). Most affected individuals have a hemizygous 3 million base
pair (Mb) de novo deletion on chromosome 22q11.2 caused by de novo meiotic non-allelic
homologous recombination events. These events take place between flanking segmental
duplications termed LCR22 (low copy repeats on 22q11.2) (Edelmann, et al., 1999). To help
positionally clone the causative gene(s) on 22q11.2, early goals were set on identifying rare
patients with smaller, nested deletions or translocations with subsets of phenotypes (Budarf,
et al., 1995; Fibison, et al., 1990; Lindsay, et al., 1995; Lu, et al., 2001; Scambler, et al.,
1991). The proximal 1.5 Mb region, flanked by LCR22s, was identified as the critical region
of the syndrome (Lindsay, et al., 1995; Morrow, et al., 1995). Because the 1.5 Mb deletion
size was large, containing many genes, it was not possible to narrow the region to a smaller
interval. Mouse models containing nested deletions (Kimber, et al., 1999; Lindsay, et al.,
1999) were generated to find candidate genes. Bacterial artificial chromosome (BAC)
transgenic mice were created to confer genetic rescue and narrow the number of candidate
genes to a few (Lindsay, et al., 2001; Merscher, et al., 2001). A single gene, Tbx1 was
identified as the strongest candidate for physical malformations (Lindsay, et al., 2001;
Merscher, et al., 2001) and inactivation by gene targeting approaches demonstrated that it is
largely responsible (Jerome and Papaioannou, 2001). While Tbx1 heterozygous mice
showed mild anomalies with reduced penetrance, homozygous null mutants died at birth
with a cleft palate, absent thymus and parathyroid glands as well as a common cardiac
outflow tract, termed a persistent truncus arteriosus.
Support this gene’s importance in humans came from rare non-deleted patients with a velo-
cardio-facial or DiGeorge syndrome phenotype that had mutations in TBX1 (MIM# 602054),
some of which alter function (Conti, et al., 2003; Gong, et al., 2001; Griffin, et al., 2010;
Stoller and Epstein, 2005; Torres-Juan, et al., 2007; Yagi, et al., 2003; Zweier, et al., 2007).
This indicates that haploinsufficiency of TBX1 in most, or mutation of TBX1 in a small
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minority of patients with related phenotypes, is responsible for the main physical
malformations occurring in patients with the syndrome.
One of the most characteristic features of 22q11DS is that it occurs with variable phenotypic
severity. With respect to structural malformations, some patients are mildly affected, for
example, with a characteristic facies and hypernasal speech, while others are severely
affected with absent thymus, cleft palate, severe hypocalcemia and/or tetralogy of Fallot.
Environmental exposures, stochastic factors or genetic modifiers are thought to be
responsible for variable expressivity. One hypothesis is that alteration of DNA sequence in a
gene on the remaining allele of 22q11.2, possibly TBX1 is the cause of this phenotypic
variability.
We have amassed a cohort of 1,022 22q11DS patients, 65% of which have a congenital
heart disease (intracardiac defects and/or aortic arch defects; CHD) while 35% have a
normal heart and aortic arch anatomy. The majority of those with a CHD had more than one
cardiovascular anomaly. The goal of the project was to determine if there are phenotype-
phenotype correlations or phenotype-genotype correlations. Unfortunately, our cohort has
too few individuals per group to consider each anomaly on its own. As a compromise, we
created phenotype enrichment groups.
In this study we performed genotype-phenotype correlations with TBX1. We found no
correlation between common SNPs or haplotypes and the CHD phenotype suggesting that
there is not a predominant common variant of TBX1 serving as a genetic modifier of
cardiovascular anomalies. This work suggests that variations elsewhere on 22q11.2 or in the
genome serve as cardiovascular modifiers. Alternatively, DNA variations in TBX1 might
explain variable expressivity for other malformations seen in association with the syndrome.
Material and Methods
Human subjects and phenotype data
Blood or saliva samples were obtained from 22q11DS subjects, with their informed consent
(Internal Review Board, 1999-201; 07-005352_CR2 CHOP IRB). A commercial
fluorescence in situ hybridization test for the 22q11.2 deletion, MLPA testing (Multiplex
ligation-dependent probe amplification, SALSA MLPA kit P250 DiGeorge; MRC Holland,
The Netherlands) or microsatellite marker analysis was part of the work up of individuals
with the syndrome for mutation analysis. TBX1 locus sequence analysis was performed on
DNAs available for 372 subjects obtained consecutively that had existing cardiac phenotype
data. Consistency of features is based upon comparison discussions with clinicians as to
clinical definitions (Bassett, et al., 2011). Half the DNA samples were obtained from
Montefiore Medical Center/Upstate Medical University (RJS) and half were obtained from
the Children’s Hospital of Philadelphia. Some of the DNAs failed to provide any sequence
data. A total of 360 DNA samples were sequenced completely. An International 22q11.2
Consortium was formed and DNA samples were obtained from additional subjects (de-
identified) resulting in a total of 1,022 DNA samples from unrelated probands with the
22q11DS. A total of 106 DNAs were obtained from Canada, 91 DNAs from Belgium, 38
DNAs from Italy, 13 DNAs from the Netherlands, 30 DNAs from France, 10 DNAs from
Atlanta, 9 DNAs from California, 18 DNAs from Montefiore, 16 DNAs from a VCFSEF
conference (Utah), 276 DNAs from CHOP, 398 DNAs from Upstate Medical University and
11 from elsewhere. The cohort used for analysis was self reported as being of Caucasian
ethnicity. We obtained phenotype information on intracardiac and aortic arch anatomy from
echocardiogram and cardiology summary reports. The entire set of DNAs were plated and
used for genotype analysis.
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There are three isoforms of human TBX1 protein, isoform A (NM_080646), B
(NM_005992) and C (NM_080647), where there are alternative terminal exons. A total of
12 exons that encode the 3 transcripts of TBX1 were sequenced in 360 consecutive 22q11.2
patients (Supp. Figure S1). All exon-intron boundaries extending >100 bp into each intron
were included. The first exon containing the 5′ UTR (untranslated region) and an additional
2,500 bp of sequence that included the putative promoter region were also sequenced. The 3′
UTR was also included in the analysis (Supp. Figure S1). Transcription start site prediction
programs suggest there are three alternative start sites in the TBX1 gene (UCSC Genome
Browser; First exon prediction track). The CpG islands corresponding to the three putative
transcription start sites in the TBX1 locus were sequenced. Short blocks of a few hundred
base pairs of DNA retained among vertebrates such as identified by the 28-Way or 17-Way
Most Conserved track (UCSC genome browser) with a LOD score >50, as chosen
arbitrarily, were also sequenced because they may contain regulatory elements. All the
evolutionary conserved non-coding regions within 5 kb of the gene body containing exons,
from 18,122,096-18,152,117 (hg18; http://www.genome.ucsc.edu/) were sequenced (Supp.
Figure S1). The human orthologous region to a previously defined enhancer for pharyngeal
apparatus expression of mouse Tbx1 (18,115,184-18,115,529;(Garg, et al., 2001) was
sequenced as well. None of the other blocks of evolutionary conserved sequences upstream
or downstream of the TBX1 gene were sequenced because their functional roles are not
known.
All primers are listed in Supp. Table S1. The PCR products were sequenced using the Big
Dye Terminator Sequencing Kit (Applied Biosystems, Carlsbad, CA) on an automated DNA
capillary sequencer (model 3730; Applied Biosystems, Carlsbad, CA). Resequencing
services were provided by the J. Craig Venter Institute under U.S. Federal Government
contract number N01-HV-48196 from the National Heart, Lung, and Blood Institute. Six
duplicated samples were used as quality control (QC). Variants that passed the QC were
used for final statistical analysis.
Genotype analysis
Common (minor allele frequency, MAF>0.05) and rare SNPs (MAF<0.05) in TBX1 were
identified from DNA sequence analysis. The SNPs were assigned to linkage disequilibrium
(LD) blocks by creating an LD matrix in Haploview software (Barrett, et al., 2005) using
TBX1 resequencing data from the 360 patients. Based upon the LD structure of the locus, 9
of the 17 common SNPs identified were then used for genotyping the entire cohort of 1,022
22q11DS subjects. We used the Sequenom iPLEX system for genotype analysis. Reagents
and protocols for multiplex PCR, single base primer extension (SBE) and generation of
mass spectra, were followed as per the manufacturer’s instructions (for complete details see
iPLEX Application Note, Sequenom Inc., San Diego, CA, PMC14630). A multiplexed assay
containing 31 SNPs (9 from TBX1; the rest from chromosomes X and Y to check for correct
gender) was designed using MassARRAY Assay Design 3.1 (Sequenom Inc., San Diego,
CA). Briefly, initial multiplexed PCR was performed in 5 μl reactions on 384-well plates
containing 10 ng of genomic DNA. Reactions contained 0.5 U FastStart Taq DNA
Polymerase (Roche, Nutley, NJ), 100 nM primers, 1× PCR buffer, 2 mM MgCl2, and 500
μM dNTPs. Following enzyme activation at 94°C for 4 min, the DNA was amplified with 45
cycles of 94°C × 20 sec, 56°C × 30 sec, 72°C × 1 min, followed by a 3 minute extension at
72°C. Unincorporated dNTPs were removed using shrimp alkaline phosphatase (0.3 U,
Sequenom Inc, San Diego, CA). Single-base extension was carried out by addition of SBE
primers at concentrations from 0.625 μM (low MW primers) to 1.25 μM (high MW primers)
using iPLEX enzyme and buffers (Sequenom Inc., San Diego, CA) in 9 μl reactions.
Reactions were desalted and SBE products measured using the MassARRAY Compact
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system, and mass spectra were analyzed using TYPER 3.4 software (Sequenom, San Diego),
in order to generate genotype calls and allele frequencies. Primer sequences are available on
request.
Statistical analysis
Phenotype-phenotype correlations—The intracardiac as well as aortic arch
phenotypes were extracted from echocardiogram and cardiology summary reports and were
entered into an Oracle-based clinical database. The individual intracardiac and aortic arch
defects that were scored include persistent truncus arteriosus (PTA), atrial septal defects
(ASD), tetralogy of Fallot (TOF), ventricular septal defects (VSD), interrupted aortic arch
type B (IAAB) and right sided aortic arch (RAA) and Pulmonary atresia or stenosis (PS).
Each individual conotruncal heart defect (CTD) or atrial septal defect, was coded to a
dichotomous variable for phenotype (0=absent, 1=present). VSD without other intracardiac
defects was termed VSD2. Contingency tables were created for the relationship between
having one individual defect and having another defect. Chi-square tests on each
contingency table were performed for pair-wise correlation between individual
cardiovascular defects. Cramer’s phi was used as the correlation coefficient to measure the
effect size (Cramér, 1946).
Common SNPs and cardiovascular defects—Nine common SNPs, MAF >0.05,
were genotyped in 1,022 DNA samples from the 22q11DS cohort as described above. Chi-
square (χ2) test or Fisher’s exact test was used to test associations between the “genotype”
(allele) and individual heart defects. Power calculations for CHD associations were
performed using the CaTS Genetic Power Calculator
(http://www.sph.umich.edu/csg/abecasis/CaTS/index.html) (Skol, et al., 2006).
Haplotype analysis—Since the TBX1 gene is located within the 22q11.2 deletion region,
and all proband DNAs have one copy of the gene, their individual haplotypes were directly
observed. We applied an X-chromosome type of model in Haploview (Barrett, et al., 2005)
to evaluate the haplotype block structure of the TBX1 gene using 17 common SNPs (MAF
>0.05) from TBX1 resequencing data for analysis as a guide. Specifically, we used the same
procedure used to analyze the non-pseudoautosomal regions of the X chromosome in males.
Very rare variant enrichment analysis—Variants with minor allele frequency (MAF)
less than <0.01 were treated as a very rare variations. We selected 45 very rare variants that
passed quality control for the analysis in 360 DNA samples. Different variants were
collapsed and tested for overall frequency differences between patients with and without
cardiovascular defects (Li and Leal, 2008). The very rare variant allele counts were
collapsed by assigning each individual a carrier/non-carrier status. This was based on the
presence or absence of very rare variant minor alleles. A simple contingency table was
constructed to test for differences in rare variant minor allele frequency between cases and
controls using the Chi-squared test (or Fisher’s exact test where necessary).
Results
Phenotype enrichment groups
Clinical data from 1,022 DNA samples from patients with the 22q11.2 deletion were used
for this study. In our cohort, 65% (664 patients) had a cardiovascular defect while 35% had
normal intracardiac and aortic arch anatomy. Most of the subjects had more than one
cardiovascular abnormality. To obtain enough patients in each phenotype category for the
genetic study, we created phenotype enrichment groups for each cardiovascular
malformation. We did not distinguish between individual subtypes of malformations.
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Phenotype enrichment groups focused on one defect at a time, while not taking other
malformations into consideration. We present the numbers of subjects in each group in
Figure 1 and the correlation analysis in Table 1. Due to the co-occurrence of cardiovascular
phenotypes, it was not possible to make specific phenotype-phenotype correlations with one
exception (Table 1). There was a significant correlation between the ASD and VSD
enrichment groups, suggesting that septal defects have a similar genetic basis in association
with the syndrome.
TBX1 gene resequencing
We obtained unambiguous DNA sequence from 360 22q11DS subjects. A total of 84 DNA
variations including SNPs (single nucleotide polymorphisms) and small indels (insertion-
deletion polymorphisms) were detected in the sequence data from all the subjects. Of these
84, only 71 DNA variations provided consistent read calls and thus passed our criteria for
quality control. Seventeen of these were common variations with a MAF >0.05 (0.07–0.44,
Supp. Table S2), while 54 were rare variations with a MAF <0.05. A total of 45 of the 54
rare variants were considered, comprised very rare variations with a MAF <0.01.
Among the 71 SNPs, three were missense, non-synonymous SNPs (rs41298838;
rs72646967, and rs4819522, Figure 2 and Supp. Table S1). The SNP rs41298838 resulted in
a Glycine to Serine amino acid substitution at position 310. This variation occurred in one
patient who had no cardiovascular abnormalities. The frequency of the G allele is 0.07 in the
Asian population but this SNP is monomorphic for the A allele in Caucasian and African
populations as noted from dbSNP (http://www.ncbi.nlm.nih.gov/projects/SNP/; submitted
by Dr. Nickerson based on one population with different ethnicity). This patient is self
reported as Asian. This variation was predicted to be “possibly damaging” in its effect on
the protein, and had a score of 0.815 by the PolyPhen software
(http://genetics.bwh.harvard.edu/pph2/) (Adzhubei, et al., 2010). The SNP rs72646967, is a
common variation that occurred in 63 patients. It resulted in an Asparagine to Histidine
amino acid substitution at position 397. The SNP rs4819522, which resulted in a Threonine
to Methionine variation at position of 350 of TBX1 isoform A, is another common SNP.
Both were predicted to be “benign” in its effects on the protein with scores of 0.000 and
0.028, respectively as determined by PolyPhen software. Protein sequence conservation
across species analysis was performed using the SIFT software
(http://blocks.fhcrc.org/sift/SIFT_seq_submit2.html) developed by Ng and Henikoff (Ng
and Henikoff, 2001; Ng and Henikoff, 2002). The first two variations, above, were predicted
to be “tolerated” with score 0.16 and 1 respectively, and the third variation was predicted to
be “damaging” with score 0.02, but with lower confidence. Overall, there was not a
significant increase or decrease in occurrence or frequency of missense SNPs in those with
and without congenital heart defects.
Six synonymous SNPs (rs72646967, rs41298814, rs2301558, rs41298840, rs13054377 and
rs72646968) were also found (Figure 2). The SNPs rs41298814, rs2301558, rs41298840 and
rs72646967 appeared commonly in our population (MAF >0.05), while rs72646968
occurred in one patient having PS. Six SNPs were identified in the 3′-UTRs of each of the
three isoforms (untranslated region). Four SNPs occurred in the 3′ UTR of TBX1 isoform C,
two occurred in the 3′ UTR of isoform A, while none occurred in the 3′ UTR of isoform B
(Figure 2). There was no enhancement of the synonymous SNPs in patients with congenital
heart defects compared to those without in our cohort of 360.
We compared the frequency and regions where the SNPs occurred versus the same content
in the emerging 1,000 Genomes Project data (Figure 3). Allele frequencies were similar,
despite the fact that DNAs from different ethnicities were sequenced in the 1,000 Genomes
Project. Figure 3). This suggests that there are no significant differences between allele
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frequencies or map locations of the SNPs in our cohort (Figure 3). Only one novel variant
was identified in our study that was not present in the 1,000 Genomes data or dbSNP build
131. This was a −/TCGC indel (insertion/deletion) variant, referred to as (Novel 23) was
identified. The variant occurred in the same DNA sample that had the minor allele of the
non-synonymous SNP, rs41298838.
Very rare variation enrichment analysis
One important possibility is that cases with cardiovascular defects or controls, without,
might show an enrichment of rare TBX1 DNA variations (Supp. Table S2). These variants
were combined and used for rare variation enrichment statistical analysis in 360 samples
(Figure 1). We did not find any enrichment of the number of very rare DNA variations
between 22q11DS cases with presence of congenital heart disease compared with 22q11DS
controls, with normal anatomy (p=0.44).
Phenotype enrichment group analysis was performed to identify subtle differences. Controls
showed enrichment of rare variants compared to two phenotype enrichment groups. Groups
with RAA and PTA had fewer rare variants than the group with normal cardiovascular
anatomy (Figure 4A). There were no rare variants in those with a RAA but no other
malformation (n=11). Based upon this, is it possible that some very rare DNA variations
might serve to protect against congenital heart disease in 22q11DS patients.
One way to detect the functional importance of rare variations is to determine whether the
major allele shows evolutionary conservation. Figure 4B shows an evolutionary pile-up of
the major/minor allele from 45 very rare variants identified in the TBX1 locus. Thirty-five of
the 45 SNPs (78%) SNPs showed evolutionary conservation among mammals, suggesting
potential functional roles. Thirty of 35 major alleles and 5 of 35 minor alleles were
conserved among different mammalian species. The minor alleles of five SNPs as well as
the minor allele (TCGC), the only novel variation (novel 23) found, were conserved among
primate species and some mammalian species.
Common SNPs and congenital heart defects
The next goal was to genotype the larger cohort of 22q11DS patients to test for association
between common SNPs and phenotype. The common TBX1 SNPs fell into three linkage
disequilibrium (LD) blocks (Figure 5). The estimate of LD structure was consistent with
data from the general population of Caucasians (CEU HapMap III; data not shown).
Based upon the LD structure, nine common SNPs were selected to represent the three LD
blocks. They were used to genotype the remaining subjects, so that we had data on all 1,022
samples. We found that there was no significant difference between the allele frequencies of
these SNPs in cases compared to controls with the 22q11.2 deletion (p>0.05) (Table 2).
Analysis of haplotypes gave similar non-significant association results (data not shown). In
order to control the bias of population stratification due to different ethnicities, the self
reported Asian (5 subjects) and African American (10 subjects) and Moroccan (1 subject)
were removed, however none of the common SNPs or haplotypes in these patients was
associated with CHDs (data not shown). The analysis was also performed between each
phenotype enrichment group versus the control group (no intracardiac and no aortic arch
defects). None of the common SNPs showed association among these groups (Supp. Table
S3)
Rare variants and haplotypes generated by common SNPs
The TBX1 gene is hemizygously deleted in 22q11DS individuals, making it possible to
directly determine haplotypes from the genotype data. Existence of the DNA sequence and
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genotyping data make it possible to further investigate the relationship between haplotype
and rare variants directly (Cohen, et al., 2004; Frazer, et al., 2009; Kryukov, et al., 2007;
Nejentsev, et al., 2009; Pritchard, 2001; Pritchard and Cox, 2002).
We investigated the relationship between common and rare haplotypes generated by 17
common SNPs and 54 rare SNPs using TBX1 resequencing data. Taking this approach, 49
haplotypes, containing common and rare SNPs were generated from the 360 samples (Figure
6). As seen in the Figure, 21 of 49 haplotypes captured 54 rare variants. The first haplotype
(Hap1: CAGGGTCTCAAAACGCA) is a common haplotype (frequency 0.272). It captured
nine rare variants with allele frequency of 0.3–0.6%. The only rare amino acid change
(rs41298838; Figure 2) was captured by this common haplotype. The second haplotype
(Hap2: CTCGGTCTCAAAACGCA, frequency 0.189) was less common than Hap1, but it
captured five rare variants including two variants with a minor allele frequency of 4.5%–
4.8%. However, the common haplotypes had different frequency of capture of rare alleles
than of rare haplotypes. Rare haplotypes including Hap11 (CTCGACCCCGGACCTCA,
frequency 0.006), Hap15 (CTCGATTTCAAAACTCG, frequency 0.003), Hap16
(CTCGGTTTCAAAACTTG, frequency 0.003), Hap19 (CACGGTTTCAAAATTCG,
frequency 0.003) and Hap20 (CAGGATTTCAAAACTCG, frequency 0.003) captured 13
rare variants with the same frequency. The data suggest that rare SNP variations could be
captured by common haplotypes.
However, the rare variants did not occur with equal frequency within common haplotypes.
This suggests that it is possible to capture most but not all the rare SNPs within haplotype
information. Sixteen of 54 rare variations could be captured by rare haplotypes generated by
surrounding common variants, and 15 of 16 rare variants could be observed with equal
frequencies with haplotypes. However, the ratio of the number of rare variants with equal
frequencies with haplotypes to rare variants captured by rare haplotypes could be
exaggerated because 14 of 16 rare variants only occurred in one patient.
Discussion
In this report, we present an analysis of TBX1 DNA sequence variations in 1,022 22q11DS
patients to determine whether they modify cardiovascular defects. We found that neither
common DNA variations themselves nor common haplotypes in TBX1 influence the
presence or severity of significant cardiovascular phenotypes. There was no enrichment of
very rare variations (MAF<0.01) in 22q11DS patients with cardiovascular defects (cases)
versus patients with normal cardiovascular anatomy (controls). Collectively, these results
suggest that common and rare variations elsewhere on 22q11.2 or in the genome influence
expression of cardiovascular phenotypes. We did observe an enrichment of very rare
variations in controls without cardiovascular malformations versus 22q11DS patients with
RAA and PTA phenotypes that may be protective by altering expression or function of
TBX1. This is supported by the fact that 67% of the SNPs show evolutionary conservation
among mammals suggesting that they may be functionally relevant. Larger studies will be
needed to understand the importance of rare SNP enrichment. In addition, functional
analysis will be required to understand how each variation could influence phenotypic
expression.
Common DNA variations
There have been previous studies performed with similar goals to find variations in TBX1
influencing cardiovascular phenotypes. In one study, a total of 39 22q11DS patients were
examined with 23 possessing a congenital heart defect while 16 had no defect (Voelckel, et
al., 2004). Single stranded conformational analysis (SSCP) was performed on TBX1 exons
2–9, followed by DNA sequencing of PCR products showing any possible variation. They
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found polymorphisms occurring in healthy individuals, but did not find any missense
variations, and suggested that mutations in TBX1 do not alter cardiac phenotypes in
22q11DS patients (Voelckel, et al., 2004). In a second study, the entire 43,776 bp TBX1
locus (hg18: 18,109,240-18,153,016) was sequenced in 29 22q11DS patients and 95
unrelated healthy controls (Heike, et al., 2010). They identified rare and common SNPs and
haplotypes, but there were too few subjects to determine if any influenced expressivity. In
the third study, an analysis was done of 174 22q11DS patients, where 123 had a
cardiovascular defect and 51 had a normal heart (Rauch, et al., 2004). They also compared
allele frequencies to that of 96 normal dizygous healthy individuals (Rauch et al., 2004) and
did not detect a significant difference in the frequency of common recurrent SNPs (Rauch, et
al., 2004). Although previous studies suggest that common TBX1 variants are not modifiers
of cardiovascular phenotypes, the studies were relatively small in size and thus, had relative
low power to detect an association. Our study generated from over a thousand patients had
more than 80% power to detect an association between CHD and TBX1 SNPs with a
genotype relative risk (GRR) of 1.2 in an additive genetic model.
Rare DNA variations
One of the greatest challenges in human genetics is to make genotype-phenotype
correlations to find genetic modifiers. In order to evaluate rare DNA variations with
significant power to draw conclusions, it was necessary to take a different approach. We
determined whether the total number of rare DNA variations in TBX1 was altered in
frequency between 22q11DS cases with a cardiovascular phenotype and 22q11DS controls
without. We found that the total number of rare variations was not enhanced in affected
cases versus controls with the 22q11.2 deletion, overall. Normal intracardiac and aortic arch
anatomy occurred in less than 1/3 of the 22q11DS cohort. It is possible that rare variants
might be enriched in controls versus cases of specific sub-phenotypes. We found rare
variations in TBX1 occur more frequently in controls than those with two sub-phenotypes,
RAA and PTA, both involving the aortic arch. None of the rare variations were deemed
pathogenic mutations. We did not find an association between common or rare haplotypes
and RAA or PTA.
Existence of rare pathogenic mutations on the remaining allele of TBX1 might lead to
neonatal lethality and would be missed in this type of cohort. Mutations in TBX1, albeit rare,
have been uncovered in a small subset of individuals with conotruncal heart defects (Conti,
et al., 2003; Gong, et al., 2001; Griffin, et al., 2010; Paylor, et al., 2006; Rauch, et al., 2010;
Torres-Juan, et al., 2007; Yagi, et al., 2003; Zweier, et al., 2007). Based upon these studies
in which mutations on one allele only occurred, it is likely that severe mutations on the
single remaining allele of TBX1 in 22q11DS patients would be lethal. Supporting this idea,
mice that are homozygous for Tbx1 null mutations die at birth with a PTA (Jerome and
Papaioannou, 2001; Lindsay, et al., 2001; Merscher, et al., 2001). Thus, we do not expect to
identify premature stop codons or highly pathogenic missense changes. We did detect two
missense changes, one was a Glycine to Serine change in a single patient and the other was
an Asparagine to Histidine change that occurred commonly, showing no association to
cardiovascular phenotype.
To determine the potential functional consequences of rare variations as a whole, we
determined whether rare variations comprised specific haplotypes, thereby serving to proxy
rare variations among the entire cohort of 1,022 samples.
To determine the possible functional consequence of rare variants enrichment, we
ascertained whether they alter nucleotides that were highly conserved among vertebrate
species. Approximately 78% of the rare SNPs showed strong evolutionary conservation
suggesting that they could influence expression levels of TBX1. In our case, it is possible
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that rare variations serve to enhance TBX1 expression levels. TBX1 function in mice and
humans is sensitive to both decreased and increased gene copy number.
TBX1 function in mice and humans is sensitive to both decreased and increased gene copy
number. Increase or decrease of Tbx1 dosage in mice results in related cardiovascular
malformations as occurring in patients (Liao, et al., 2004; Zhang and Baldini, 2008).
Humans with the 22q11.2 duplication have been described and are increasing in diagnosis
due to application of microarray comparative genome hybridization technologies. The
duplication is the reciprocal product of an inter-chromosomal non-allelic homologous
recombination event in meiosis (Edelmann, et al., 1999). A developmental delay disorder
with associated congenital malformations including related heart defects occurs as a result of
the duplication, but with reduced penetrance (Ensenauer, et al., 2003; Ou, et al., 2008; Yobb,
et al., 2005). It is possible that three copies of TBX1 instead of two copies cause similar
types of physical malformations. This is relevant to the results obtained in which 22q11DS
patients with RAA or PTA have fewer rare TBX1 DNA variations than those with no
cardiovascular defects and suggests that these variants might alter TBX1 levels or function
and serve as protective roles. A few years ago, human TBX1 missense mutations were found
to cause gain of function resulting in 22q11DS related phenotypes (Zweier, et al., 2007). In
the study by Zweier et al., they followed up the mutations in non-deleted patients by testing
transcriptional activation of the mutants in cell culture and found enhanced activity (Zweier,
et al., 2007). Overall, these results suggest that the TBX1 gene is sensitive to altered dosage
and variations that effect protein expression or function could alter phenotypes.
Other genes on 22q11.2 could influence expressivity
Studies in mice suggest that modifiers may exist because genetic background strongly
influences phenotype. There may be many different causative modifiers in humans, some of
which might be DNA variations in genes on the remaining allele of 22q11.2 as the other
copy is no longer present. A recent release of the newest human genome assembly (hg19)
has been annotated in the UCSC and Ensembl genome browsers. Currently, there are over
60 known and predicted genes in the 3 Mb region (Hg19, chr22:18,809,439-21,436,728;
2,627,290bp; http://genome.ucsc.edu) and 39 in the nested 1.5 Mb critical region
(chr22:18,809,439-20,328,689; 1,519,251 bp). It is possible that DNA variations in other
genes on the remaining allele influence expressivity of cardiovascular defects to a greater
extent than TBX1. Among the genes in the 22q11.2 interval, CRKL (MIM# 602007),
encoding a cytoplasmic adaptor to receptor tyrosine kinases, has been shown in mouse
models to interact genetically with TBX1 (Guris, et al., 2006). Tbx1+/− mouse embryos had
VSDs and mild aortic arch branching defects such as abnormal origin of the right subclavian
artery at reduced penetrance (Jerome and Papaioannou, 2001; Lindsay, et al., 2001;
Merscher, et al., 2001), whereas Tbx1−/− mouse embryos had a PTA with obligate VSD
(Jerome and Papaioannou, 2001; Lindsay, et al., 2001; Merscher, et al., 2001). Inactivation
of both copies of Crkl in mice resulted in similar defects as in humans with the deletion or
related mouse models that act in the Tbx1 genetic pathway (Guris, et al., 2006). Crkl−/− null
mutants had a VSD, aortic arch anomalies (IAAB, abnormal origin of the right subclavian
artery) and double outlet right ventricle. Tbx1+/−; Crkl+/− mice had the full spectrum of
cardiovascular defects as seen in 22q11DS patients. One may suggest based upon mouse
genetic data that DNA variations in CRKL might alter expressivity of cardiovascular
malformations.
Another important gene on the remaining 22q11.2 allele to investigate is the Ubiquitin
fusion degradation 1 homolog to yeast Ufd1 gene (UFD1L; MIM# 601754). It is a
component of a complex that facilitates degradation of polyubiquitin-tagged proteins
(Meyer, et al., 2000; Ye, et al., 2001). A patient was identified with a hemizygous mutation
in UFD1L that had similar cardiovascular malformations as in 22q11DS patients
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(Yamagishi, et al., 1999), although its role as a candidate gene for non-deleted patients with
a 22q11DS phenotype is not clear (Wadey, et al., 1999). In addition to UFD1L, another
gene, histone cell cycle regulation defective homolog A (HIRA; MIM# 600237 [S.
cerevisiae]); TUPLE1; TUP1-like enhancer of split protein 1), has been studied for its role in
etiology of the main clinical features of 22q11DS (Halford, et al., 1993; Magnaghi, et al.,
1998). Inactivation of one allele of Hira in mouse models did not result in a phenotype while
inactivation of both copies resulted in gastrulation defects (Roberts, et al., 2002). Similar to
UFD1L, HIRA has had limited follow up studies in comparison to that of TBX1 and CRKL,
which when inactivated in the mouse cause cardiac outflow tract defects. Overall, it would
be useful to perform DNA sequencing of exons of all the genes on the remaining allele of
chromosome 22q11.2 to identify common or rare variants that alter the phenotypic
spectrum.
Genes elsewhere in the genome that can alter expressivity
Previous mouse genetic studies have suggested that it is not genes on the other allele of
22q11.2 that can influence expressivity but variants elsewhere in the genome. In a study of a
mouse model containing a deletion of the region of synteny to 22q11.2, termed Df1/+, it was
found that varying the background of the remaining allele had no alteration in phenotype
(Taddei, et al., 2001). Genetic factors due to varying genetic background elsewhere, were
hypothesized to influence expressivity (Taddei, et al., 2001).
To identify genetic modifiers, several candidate gene approaches were undertaken by using
mouse models and intercrossing mutant mice with Tbx1 mouse mutants. One important gene
downstream of Tbx1 is Fgf8 (Fibroblast growth factor ligand 8). Foxa2, a forkhead
transcription factor gene, might act upstream of Tbx1, which might regulate Fgf8 protein
levels (Hu, et al., 2004). Hypomorphic Fgf8 mutant mouse embryos had similar
malformations as homozygous Tbx1 null mutant embryos suggesting a possible shared
genetic pathway (Park, et al., 2006) (Ilagan, et al., 2006). Epistasis studies by intercrossing
Tbx1+/− mice with Fgf8+/− mice showed a much more severe phenotype than either alone
(Vitelli, et al., 2002). Of interest, there is also a genetic interaction in the mouse between
Crkl and Fgf8 (Park, et al., 2006); as well as one between all three genes, Tbx1, Crkl and
Fgf8 (Guris, et al., 2006), indicating the importance of the three genes for development of
the outflow tract. In addition to these, a genetic interaction was identified between several
additional genes including Pitx2, Gbx2, Chd7 and Hes1, among others (Calmont, et al.,
2009; Nowotschin, et al., 2006; Randall, et al., 2009) (van Bueren, et al., 2010). Mutations
in PITX2 causes Reiger syndrome (MIM# 180500), however cardiac malformations are not
a hallmark feature of the disorder in humans (Semina, et al., 1996). Among the others, Chd7
is particularly interesting because mutation or deletion of CHD7 in humans causes
CHARGE syndrome (MIM# 214800) with associated cardiac outflow tract defects such as
VSD and TOF [(Vissers, et al., 2004) CHARGE, coloboma, heart defects, atresia choanae,
retarded growth, genital abnormalities and ear defects)]. A genetic interaction between the
two genes indicates that the two diseases, 22q11DS and CHARGE syndrome share common
pathways (Randall, et al., 2009)
Unbiased gene profiling approaches have been performed to identify new genes or pathways
downstream of Tbx1 (Ivins, et al., 2005; Liao, et al., 2008). From this, there are many genes
to pursue in human DNAs by genotyping for common SNPs or sequencing to uncover rare
variations. Nonetheless, truly unbiased genome wide approaches must be undertaken to
identify common or rare variations influencing the expressivity of cardiovascular defects.
One approach would be to perform genome wide association studies (GWAS) to identify
loci harboring common SNP variations. This would involve genotyping many hundreds if
not thousands of 22q11DS patients with high-density microarrays containing up to a million
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or more SNPs. The goal would be to perform genotype-phenotype correlations in a similar
manner as for TBX1.
Another outcome from performing a GWAS is the ability to also identify common and rare
genomic deletions or duplications referred to as copy number variations (CNVs). Such
CNVs might uncover second hit loci that interact with genes on the 22q11.2 region. Finally,
whole exome sequencing analysis has to potential to uncover rare DNA variations that act as
second hit mutations influencing expressivity. For exome sequence analysis, mutations will
be found but the challenge will be to determine which are responsible for influencing
expressivity.
Environmental exposures, stochastic factors as well genetic modifiers are likely responsible
for variable expressivity in 22q11DS. It is clear that both environmental (intra-uterine) and
stochastic factors play a significant role in influencing expressivity. Exposure to high or low
levels of retinoic acid (activated form of vitamin A) or alcohol during pregnancy results in
similar malformations as those occurring in 22q11DS patients (Burd, et al., 2007; Ruckman,
1990). Further, evidence for non-DNA based etiologies derives from studies of monozygotic
twins with the disorder. In a few studies of monozygotic twins with the syndrome it was
found that most have discordant phenotypes (Lu, et al., 2001; Vincent, et al., 1999;
Yamagishi, et al., 1998). One problem with the studies is that not many monozygotic twin
pairs have been analyzed. Nonetheless, this indicates that environmental and stochastic
factors influence expressivity.
In summary, we found that neither common SNPs nor haplotypes in TBX1 could explain the
basis of phenotypic expression variability of congenital heart disease in 1,022 patients with
22q11DS. In our cohort, 65% of 22q11DS patients with the 22q11.2 deletion have a
congenital heart defect while 35% do not. The finding that rare variations were enriched in
those with no cardiovascular defect as compared to those with RAA and PTA, and that a
subset of those DNA variants were highly conserved among vertebrate species suggests
possible functional roles. More work needs to be done examining common and rare DNA
variations of additional genes on 22q11.2 and elsewhere to determine their role in altering
expressivity of 22q11DS. It is also possible that although TBX1 variations do not influence
cardiovascular phenotypes, they may be important for craniofacial or other malformations
associated with the syndrome.
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Cardiovascular phenotype enrichment groups. The stacked bar chart represents the total
number of samples used for TBX1 resequencing (Cohort). The number in each group is also
indicated above the bar chart (Cohort). Those with a significant intracardiac or aortic arch
malformation are referred to as having a congenital heart defect (CHD). Total samples of
isolated individual malformations were shown on the top of the figure (Isolate). For
example, the total number of patients with atrial septal defects (ASDs) is 80. Among the 80,
16 had an ASD but no other defects (not shown in the table). The rest had ASD as well as
other cardiovascular defects. TBX1 sequencing was performed on 48 ASD patients, while
genotyping for common SNP variants was performed in all of them. The number 32 derives
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from subtracting 48 from 80. There were 385, 22q11DS subjects with VSDs (ventricular
septal defects; 52 samples with VSD only). VSD occurs as part of tetralogy of Fallot (TOF)
and persistent truncus arteriosus (PTA). Among those in the VSD enrichment group, 150
had a VSD that was not associated with TOF or PTA (52 samples had VSD but no other
intracardiac defect). A separate designation was made for those with a VSD but not in
association with TOF or PTA (VSD2). There were 150 with VSD as the only intracardiac
defect. A total of 181 patients had TOF; 75 were subjected to TBX1 resequencing and all
were genotyped. Sixty 22q11DS patients had TOF but no aortic arch defect or ASD (not
shown in the table). Pulmonic stenosis (PS) occurs in association with TOF and it can co-
occur with a VSD. In some of the echocardiogram summaries, PS and VSD were indicated
but TOF wasn’t. In those situations, we did not assume the patient had a TOF. A total of 124
comprised the PS enrichment group (pulmonic atresia or stenosis). Sixty were subjected to
TBX1 resequencing and all were genotyped. Among those with PS, only 4 had this
malformation and no other intracardiac or aortic arch anomaly. Only 28 of 55 had a PTA but
no other anomaly. Fifty-four patients had an interrupted aortic arch type B (IAAB); 34 were
sequenced and all were genotyped. Only 4 total had an IAAB but no other intracardiac or
aortic arch defect. A total of 137 had a right-sided aortic arch (RAA) and 77 were subjected
to TBX1 resequencing, while all were genotyped. Thirty-three patients had RAA as the only
cardiovascular defect. In total, 664 patients had an intracardiac and/or aortic arch
malformation (CHD; cases) and were genotyped while 231 were subjected to TBX1
resequencing. A total of 358 patients had no detectable CHD (controls), and 112 were
sequenced, while all were genotyped. Defects such as small patent foramen ovale or
abnormal branching of the subclavian arteries were not always detected or noted and were
not included in the analysis.
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DNA variations in TBX1 exons. Three TBX1 isoforms (TBX1 isoform B, top,
18,124,226-18,151,112; TBX1 isoform A, bottom, 18,124,226-18,147,068; TBX1 isoform
C, middle, 18,124,226-18,134,855 on human genome hg18) were shown on the “RefSeq
Genes” track in the UCSC Genome Browser. Custom track “Variations in TBX1 exons” was
added to visualize the DNA variations found in the exons from DNA sequence analysis of
360 22q11DS patients. Each bar represents a variation, color coded as red, green and blue to
represent non-synonymous, synonymous and UTR variations, respectively.
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Comparison of frequency SNPs to public databases. We performed a comparison of data on
the MAF (Minor allele frequency) of SNPs between the 22q11DS study and 1,000 Genome
Project (http://www.1000genomes.org/;) (Durbin, et al., 2010). Three custom tracks are
shown in addition to the RefSeq track in a snapshot of the UCSC Genome Browser (hg18).
The “1,000Genome” track shows the MAFs of all DNA variations identified in the TBX1
locus. The data were extracted from pilot data (release 2010_07) from the 1,000 Genome
Project. The next two tracks, entitled “1,000 Genome-2″ and “ 22q11DS” track show the
MAFs of DNA variants indentified in the same regions of TBX1 that were sequenced in our
cohort. The height of the lines representing each variant depicts the MAF, which turn out to
be similar in both datasets. Detailed information on DNA variations identified by TBX1
resequencing is in Supp. Table S2.
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(A) Enrichment of very rare DNA variations. “Control”, “ CHDs” (Congenital heart
defects=CTDs+ASD), “RAA” and “PTA” custom tracks were added to the UCSC Genome
Browser as shown. The custom tracks indicate the type of rare variations (MAF<0.01)
identified by TBX1 resequencing analysis in each phenotype enrichment group (total number
of subjects and definition of each phenotype group is in Figure 1). Each line or bar
represents a different rare SNP. The orange vertical lines represent variations from the
putative promoter region, black represents intronic variants and blue are variants from the
3′-UTR. The red bar represents a nonsynonymous variant and a green bar denotes a
synonymous variation. Detailed information of rare variations used for DNA enrichment
analysis is shown in Supp. Table S2. (B) Multiple sequence alignment of 45 very rare TBX1
variants (MAF<0.01). Multiple alignment data from 44 vertebrate species generated using
multiz and other tools in the UCSC/Penn State Bioinformatics comparative genomics
alignment pipeline were extracted using Galaxy (http://main.g2.bx.psu.edu/), a web-based
genome analysis tool (Blankenberg, et al., 2010; Goecks, et al., 2010). Both Galaxy and then
Jalview (Waterhouse, et al., 2009) were used to edit alignments. The species in the database
with significant missing sequence were discarded and only results from 24 mammals are
shown. The first two rows indicate the major or minor allele identified in the 22q11DS
patient cohort. Each row below represents one of the 24 mammalian species. In general,
each column represents a rare DNA variation except for the 8th variation that has a three
base and 24th that has a four base indel. The most intense blue color corresponds to the most
conserved SNPs. A total of 30 major alleles from the 22q11DS cohort show evolutionary
conservation. Five minor alleles show conservation as indicated. The minor allele (TCGC),
the only novel variation (novel 23) found in the sample, was conserved among most
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mammalian species. Detailed information on the 45 rare variations is shown in Supp. Table
S2.
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Linkage disequilibrium (LD) plot of 17 common SNPs from the TBX1 resequencing data.
An LD matrix was generated from DNA sequence data, using the X-chromosome model in
Haploview 4.2. Seventeen common SNPs with a MAF >0.05 were used to generate the plot.
The SNPs highlighted in green are those selected to genotype in the whole cohort of 1,022
patients. Standard (D′/LOD) models were used to create the LD color scheme. The value in
each pairwise box is the r2 value. We found that there were three LD blocks in the TBX1
locus.
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Haplotypes of common SNPs (MAF>0.05) and 54 rare variants (MAF<0.05). A total of 54
rare variants (MAF<0.05) identified by TBX1 resequencing were shown in each column (the
order of variants is according to Supp. Table S2). Each row represents a patient that carries
one or more of the 54 rare variants (the major allele is a black dot; the minor allele is
indicted in bold red font). Each haplotype group is indicated as Hap1–21 (Hap22–49 which
didn’t occur in any patient with rare variations, is not shown.). They were determined by the
allele pattern of the 17 common SNPs. Some patients shared common haplotypes. Twenty-
one of 49 haplotypes captured all rare variations (MAF<0.05) in a total of 77 subjects. Hap1
(CAGGGTCTCAAAACGCA), Hap2 (CTCGGTCTCAAAACGCA) and Hap3
(TTCGACCCCGGACCTCG) were common haplotypes (frequency>0.05) generated by 17
common SNPs from TBX1 resequencing data. Hap4 to Hap7 were less common haplotypes
(0.01<frequency<0.05) and hap8 to hap21 were very rare haplotypes (frequency<0.01). For
each variant, the boxes highlighted in different colors represent the minor allele of rare
variants observed in the subjects with the given haplotypes indicated (Hap1–21).
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The left lower panel shows the Chi-square p value
b
the right shows Cramer’s phi correlation coefficient.
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